346729-48-4

Basic information

• Product Name: 1-(3-chloro-5-(trifluoromethyl)phenyl)piperazine
• Synonyms: 1-(3-chloro-5-(trifluoromethyl)phenyl)piperazine
• CAS NO: 346729-48-4
• Molecular Weight: 264.678
• Mol File: 346729-48-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1-(3-chloro-5-(trifluoromethyl)phenyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-chloro-5-(trifluoromethyl)phenyl)piperazine(346729-48-4)
• EPA Substance Registry System: 1-(3-chloro-5-(trifluoromethyl)phenyl)piperazine(346729-48-4)

Safety Data

• Hazardous Substances Data: 346729-48-4(Hazardous Substances Data)

Upstream product

• 928783-85-1 1-bromo-3-chloro-5-(trifluoromethyl)benzene 
• 1542213-26-2 C₁₆H₂₀ClF₃N₂O₂ 
• 110-85-0 piperazine 
• 54773-20-5 1,3-dichloro-5-(trifluoromethyl)benzene 

Downstream Products

• 346728-98-1 1-(3-Chloro-5-trifluoromethyl-phenyl)-4-propyl-piperazine 

Relevant articles and documents

LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME

LpxH targeting compounds, compositions thereof, as well as methods for for making and using the same are disclosed herein. The LpxH target compounds typically have a structure pursuant to Formula (I) and/or a salt thereof, wherein Rb is selecte

4-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)- N -(4-methoxypyridin-2-yl) piperazine-1-carbothioamide (ML267), a potent inhibitor of bacterial phosphopantetheinyl transferase that attenuates secondary metabolism and thwarts bacterial growth

4′-Phosphopantetheinyl transferases (PPTases) catalyze a post-translational modification essential to bacterial cell viability and virulence. We present the discovery and medicinal chemistry optimization of 2-pyridinyl-N-(4-aryl)piperazine-1-carbothioamides, which exhibit submicromolar inhibition of bacterial Sfp-PPTase with no activity toward the human orthologue. Moreover, compounds within this class possess antibacterial activity in the absence of a rapid cytotoxic response in human cells. An advanced analogue of this series, ML267 (55), was found to attenuate production of an Sfp-PPTase-dependent metabolite when applied to Bacillus subtilis at sublethal doses. Additional testing revealed antibacterial activity against methicillin-resistant Staphylococcus aureus, and chemical genetic studies implicated efflux as a mechanism for resistance in Escherichia coli. Additionally, we highlight the in vitro absorption, distribution, metabolism, and excretion and in vivo pharmacokinetic profiles of compound 55 to further demonstrate the potential utility of this small-molecule inhibitor.